Illumina, Inc. research snapshot
ILMN AI stock analysis currently sees Illumina as a high-quality sequencing tools franchise benefiting from consumables demand and NovaSeq X adoption, while its valuation leaves little room for slower growth, China disruption, or margin pressure. At the July 11, 2026 cutoff, ILMN traded near $192.03 with a verified market capitalization of $29.05 billion. Q1 2026 revenue grew 4.8% year over year and management raised guidance, but the company still carries net debt, faces competition and policy risk in Greater China, and trades at elevated earnings and free-cash-flow multiples. This page is informational only and not investment advice.
Current price
$192.03
Market cap
$29.05 billion
AI score
59 / 100
Rating
Improving sequencing franchise with a demanding valuation and China risk
Trend status
Strong uptrend, extended above moving averages
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Illumina sells sequencing instruments and high-margin consumables used in research and clinical workflows. The installed base supports repeat purchases, but instrument demand is cyclical and tied to customer funding and capital budgets. | High |
| Moat | Workflow integration, installed instruments, consumables compatibility, data familiarity, scientific reputation, and scale create switching costs. The moat is challenged by lower-cost and alternative sequencing platforms. | Medium-high |
| Management | CEO Jacob Thaysen has focused the company on the core franchise, operating discipline, NovaSeq X adoption, and shareholder returns. The next proof point is durable growth without sacrificing innovation or margins. | Medium |
| Financial trend | FY2025 revenue was $4.343 billion and Q1 2026 revenue was $1.091 billion, up 4.8% year over year. Q1 GAAP operating margin was 19.2%, and Q1 free cash flow was $251 million. | High |
| Valuation | At $192.03, verified math gives about 34.8x TTM EPS, 10.9x book value, and 29.8x free cash flow. The multiple assumes meaningful earnings progress and limits valuation margin of safety. | High |
| Technical trend | ILMN was above its 50-day and 200-day moving averages, with RSI near 74 in the current public snapshot. The trend is positive, but the momentum reading raises pullback risk. | Medium-high |
| Risk level | Risk is medium-high. China policy, funding cycles, competitor price and technology moves, tariffs, instrument demand, leverage, and execution against guidance can all move the valuation. | High |
| AI confidence | Reported data is well documented, but AI cannot know the pace of genomic adoption, policy decisions, customer spending, or competitive technology transitions. | High data confidence |
| Investment certainty | The franchise is easier to understand than a clinical-stage biotech, yet investment certainty is lower than business quality because the current price requires sustained operational progress. | Medium-low |
ILMN AI stock forecast
The ILMN AI stock forecast uses audited, three-year scenario math rather than a point prediction. It applies different EPS growth and terminal multiple assumptions to current TTM EPS of $5.52, so the ranges show what must go right or wrong rather than a promised future price.
$300 to $330
More likely if NovaSeq X and clinical sequencing accelerate consumables growth, China access improves, operating margins expand, buybacks reduce share count, and the market sustains a premium multiple for a stronger recurring-revenue profile.
$205 to $225
More likely if management delivers its 2026 revenue and non-GAAP EPS guidance, consumables continue to offset uneven instrument sales, and the valuation settles near 30x a three-year EPS outcome.
$125 to $140
More likely if China restrictions persist or worsen, customer capital spending weakens, competitors take share, tariffs or pricing pressure hurt margins, or earnings grow only modestly while the premium multiple contracts.
ILMN AI technical analysis
ILMN AI technical analysis uses the July 7, 2026 public market snapshot near $192.03. This static page does not fetch request-time market data. Price was well above the 50-day and 200-day moving averages, while RSI near 74 indicated strong but extended momentum.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $192.03 | Public quote snapshot around the July 11, 2026 data cutoff. |
| Recent high and resistance | $196.66 | July 7 intraday high and the nearest visible resistance reference from the current quote snapshot. |
| Near support | $189.09 | July 7 intraday low. A live chart should confirm whether this level attracts demand. |
| 50-day moving average | $155.63 | StockAnalysis public statistics snapshot. Price was above this average. |
| 200-day moving average | $131.17 | StockAnalysis public statistics snapshot. Price was above this average. |
| Momentum | Strong, RSI 74.35 | The RSI reading indicates strong momentum but also a more extended short-term condition. |
| Volume | 1.94 million average shares | 20-day average volume in the public statistics snapshot. Breakouts should be confirmed against live volume. |
| Volatility | Beta 1.47 | The five-year beta was above the market average, so price changes can exceed broad-index moves. |
| Invalidation | Sustained close below the 50-day average | A sustained break below roughly $156 would weaken the medium-term trend framework and should trigger a review of both price action and fundamentals. |
ILMN AI trading strategy
The ILMN AI trading strategy is a research and risk-control framework, not a personalized instruction. It combines technical confirmation with earnings, consumables demand, NovaSeq X adoption, China policy, margins, cash flow, debt, and buyback updates.
Require a decisive move through the recent $196.66 high with live volume confirmation, then check that earnings, China access, customer demand, and guidance have not changed materially.
Define risk before entry. A failed breakout or sustained close below the 50-day average can be a rules-based invalidation condition instead of a reason to average down automatically.
If ILMN retraces toward the 50-day average without weaker guidance, China policy escalation, competitive loss, or margin deterioration, assess whether price stabilizes alongside updated fundamentals.
Do not assume a lower price is better value. Reassess the thesis if the decline follows new evidence on sequencing demand, customer funding, tariffs, or competitive pricing.
Track consumables and instrument revenue, NovaSeq X adoption, regional revenue, China policy, gross margin, operating margin, free cash flow, cash and debt, repurchases, and 2026 guidance at each material update.
Refresh scenario ranges after quarterly results, material policy changes, or product and competitive announcements. A quality franchise can still produce poor returns when expectations and valuation are high.
Investment research summary
Illumina earns revenue by selling sequencing instruments and then supplying consumables, services, and workflow support. Customers pay for reliable genomic data used in research, drug development, population studies, and growing clinical applications.
The moat comes from a large installed base, consumables compatibility, validated laboratory workflows, data familiarity, scientific reputation, intellectual property, and scale. It can narrow if competitors offer comparable results at meaningfully lower total cost.
The thesis can fail if China restrictions continue, customer budgets tighten, instruments sell below plan, new platforms erode share or pricing, tariffs lift costs, margins miss targets, debt constrains flexibility, or valuation compresses despite operational progress.
Management is prioritizing the core sequencing franchise after the GRAIL separation, with a stated focus on growth, operating discipline, and share repurchases. Investors should test the strategy against recurring revenue growth, R&D effectiveness, margin delivery, and capital allocation.
Genomics remains a long-duration healthcare and life-science trend as sequencing moves deeper into clinical and research workflows. Adoption is not linear because reimbursement, regulation, laboratory budgets, customer funding, and technology choices shape demand.
The verified $29.05 billion market capitalization and roughly 34.8x TTM PE value a successful recovery in growth and profitability. The margin of safety is limited because slower growth or multiple compression can outweigh steady operating execution.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ILMN price and shares | $192.03 and 151.30 million shares outstanding in the July 7 public snapshot | StockAnalysis quote and statistics | July 11, 2026 |
| Market capitalization | $29.05 billion, verified with financial_rigor.py using $192.03 and 151.30 million shares at 0.01% variance | StockAnalysis statistics | July 11, 2026 |
| FY2025 revenue and net income | $4.343 billion revenue and $850 million net income, cross-validated against Macrotrends at 0.00% variance | Illumina 2025 Form 10-K | July 11, 2026 |
| FY2025 revenue mix and China impact | $3.227 billion consumables, $482 million instruments, and $634 million service and other revenue. Greater China revenue declined $65 million after inclusion on the Unreliable Entities List. | Illumina 2025 Form 10-K | July 11, 2026 |
| Q1 2026 results and guidance | $1.091 billion revenue, 19.2% GAAP operating margin, $0.87 GAAP diluted EPS, and 2026 revenue guidance of $4.52 billion to $4.62 billion | Illumina Q1 2026 results | July 11, 2026 |
| Cash, debt, and free cash flow | $1.16 billion cash and short-term investments at Q1 close, $2.54 billion total debt, and $974 million TTM free cash flow. Cash was cross-validated within 0.22%. | Illumina Q1 2026 results and StockAnalysis statistics | July 11, 2026 |
| Valuation math | financial_rigor.py calculated 34.79x PE, 10.90x PB, 29.82x P/FCF, and 3.35% FCF yield from the published price, EPS, book value, and FCF per share inputs. | Pineify financial_rigor.py with StockAnalysis inputs | July 11, 2026 |
| Technical inputs | 50-day moving average $155.63, 200-day moving average $131.17, RSI 74.35, and 20-day average volume 1.94 million shares. | StockAnalysis statistics | July 11, 2026 |
This ILMN page is an informational research tool, not investment advice or a recommendation to buy or sell securities. Forecast scenarios use available data and assumptions that may be wrong. Sequencing demand, China policy, competition, financial results, and market conditions can change quickly, and users should verify current information and consider professional advice before making an investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
